Pfizer Pipeline. August 9, 2012
|
|
|
- Allen Ryan
- 6 years ago
- Views:
Transcription
1 Pfizer Pipeline August 9, 2012
2 Disclaimer As some programs are still confidential, some candidates may not be identified in this list. In these materials, Pfizer discloses Mechanism of Action (MOA) information for candidates from 3 through regulatory approval. With a view to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or represent significant commercial opportunities. The information contained on these pages is correct as of August 9, Visit Pfizer.com/pipeline, Pfizer s online database where you can learn more about our portfolio of new medicines and find out more about our Research and Development efforts around the world. 2
3 Table of Contents Pfizer Pipeline Snapshot 4 Cardiovascular & Metabolic Diseases 5 Inflammation & Immunology 6 Neuroscience & Pain 7 Oncology 9 Vaccines 10 Other Areas of Focus 11 Projects Discontinued Since Last Update 12 3
4 Pfizer Pipeline Snapshot Discovery Projects 8 programs advanced or are new Pfizer Pipeline Snapshot as of August 9, In Reg Total 87 Pipeline represents progress of R&D programs as of August 9, 2012 Included are 65 NMEs, 20 additional indications, plus 2 biosimilars 8 projects discontinued since last update Recent Approval - Lyrica for treatment of central neuropathic pain due to spinal cord injury Discovery Projects 3 programs advanced or are new Pfizer Pipeline Snapshot as of May 10, In Reg Total 87 Pipeline represents progress of R&D programs as of May 10, 2012 Included are 64 NMEs, 22 additional indications, plus 1 biosimilar 6 projects discontinued since last update Recent Approval - ELELYSO (taliglucerase alpha) for treatment of adults with a confirmed diagnosis of type 1 Gaucher disease (U.S.) 4
5 Pfizer Pipeline August 9, 2012 Therapeutic Area Compound Name Viviant Eliquis (apixaban) Mechanism of Action Selective Estrogen Receptor Modulator Factor Xa Inhibitor Osteoporosis Treatment and Prevention (U.S.) Stroke Prevention in Atrial Fibrillation (U.S./EU) Cardiovascular and Metabolic Diseases RN316 (PF ) PF PF Hypercholesterolemia (Biologic) Diabetes Mellitus-Type 2 Diabetic Nephropathy CVX 096 (PF ) Diabetes Mellitus-Type 2 (Biologic) 1 apixaban Factor Xa Inhibitor Venous Thromboembolism Prevention (U.S.) 3 Eliquis (apixaban) Factor Xa Inhibitor Venous Thromboembolism Treatment 3 PF Diabetes Mellitus-Type 2 OAP-189 (PF ) Diabetes Mellitus-Type 2, Obesity (Biologic) 1 PF Diabetic Nephropathy 1 PF Diabetes Mellitus-Type 2 (Biologic) 1 PF Diabetes Mellitus-Type 2 1 PF Hypercholesterolemia (Biologic) 1 PF Acute Coronary Syndrome 1 New or Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com 5
6 Pfizer Pipeline August 9, 2012 (cont d) Therapeutic Area Compound Name Mechanism of Action tofacitinib (CP ) JAK Inhibitor Rheumatoid Arthritis (U.S./EU) tofacitinib (CP ) JAK Inhibitor Psoriasis (Oral) 3 tofacitinib (CP ) JAK Inhibitor Ulcerative Colitis 3 PF Rheumatoid Arthritis PF Ulcerative Colitis (Biologic) Inflammation and Immunology anrukinzumab (IMA-638) Ulcerative Colitis (Biologic) PF Crohn s Disease (Biologic) PF tofacitinib (CP ) Crohn s Disease, Lupus, *Rheumatoid Arthritis (Biologic) Psoriatic Arthritis, Ankylosing Spondylitis, Psoriasis (Topical), Crohn s Disease PF (EXC 001) Dermal Scarring PD Lupus (Biologic) 1 PF Rheumatoid Arthritis (Biosimilar) 1 New or Biosimilar * Note: Additional indications in 1 6
7 Pfizer Pipeline August 9, 2012 (cont d) Therapeutic Area Compound Name Mechanism of Action Neuroscience & Pain tafamidis meglumine Transthyretin (TTR) Dissociation Inhibitor Transthyretin familial amyloid polyneuropathy (U.S.) Celebrex COX-2 Chronic Pain (U.S.) Remoxy ALO-02 Oxycodonenaltrexone core Mu-type opioid receptor (MOR-1) Agonist Mu-type opioid receptor (MOR-1) Agonist Moderate to Severe Pain (U.S.) Moderate to Severe Pain 3 Lyrica Alpha-2 Delta Ligand Peripheral Neuropathic Pain 3 Lyrica Alpha-2 Delta Ligand CR (once a day dosing) 3 tanezumab Nerve Growth Factor Inhibitor OA Signs and Symptoms (Biologic) (On Clinical Hold) 3 PF Schizophrenia Eladur Chronic Pain (Will return rights to develop and commercialize to DURECT effective August 30, 2012) PF Stroke Recovery tanezumab Chronic Pain (Biologic) (On Clinical Hold) New or 7
8 Pfizer Pipeline August 9, 2012 (cont d) Therapeutic Area Compound Name Mechanism of Action PF Chronic Pain 1 Neuroscience & Pain (cont d) PF (AAB-003) Alzheimer s Disease (Biologic) 1 PF Schizophrenia, Sensorineural Hearing Loss 1 PF (SAM-760) Alzheimer s Disease 1 PF Schizophrenia 1 PF Acute and Chronic Pain 1 New or Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com 8
9 Pfizer Pipeline August 9, 2012 (cont d) Therapeutic Area Oncology Compound Name crizotinib axitinib bosutinib dacomitinib (PF ) Xalkori (crizotinib) Mechanism of Action c-met-alk Inhibitor VEGF Tyrosine Kinase Inhibitor Abl and src-family kinase inhibitor pan-her Inhibitor c-met-alk Inhibitor Previously Treated ALK-Positive Advanced Non-Small Cell Lung Cancer (EU) 2 nd Line Advanced Renal Cell Carcinoma after failure of prior systemic treatment (EU) Previously Treated Chronic Myelogenous Leukemia (U.S.), Chronic Myelogenous Leukemia (EU) Previously Treated Advanced Non-Small Cell Lung Cancer ALK-Positive 1st and 2nd Line (supports full approval in the U.S.) Non-Small Cell Lung Cancer, *Cancer 3 3 Inlyta (axitinib) VEGF Tyrosine Kinase Inhibitor Advanced Renal Cell Carcinoma in treatment-naïve patients 3 Inlyta (axitinib) VEGF Tyrosine Kinase Inhibitor Renal Cell Carcinoma Adjuvant (Asia only) 3 Sutent Multiple Tyrosine Kinase Inhibitor Renal Cell Carcinoma Adjuvant 3 inotuzumab ozogamicin Aggressive Non-Hodgkin s Lymphoma (Biologic) 3 inotuzumab ozogamicin Acute Lymphoblastic Leukemia (Biologic) 3 Inlyta (axitinib) Liver Cancer New or Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com * Note: Additional indications in 1 9
10 Pfizer Pipeline August 9, 2012 (cont d) Therapeutic Area Compound Name Mechanism of Action dacomitinib (PF ) Cancer PD Cancer CVX 060 (PF ) Renal Cell Carcinoma, *Cancer (Biologic) PF Endometrial Cancer, *Cancer Oncology (cont d) Vaccines PF Endometrial Cancer, *Cancer PF Cancer 1 PF Cancer (Biologic) 1 PD Cancer (in combination with PF ) 1 PF Cancer (Biologic) 1 PF Cancer (Biologic) 1 PF Metastatic Breast Cancer (Biosimilar) 1 PF Acute Myelocytic Leukemia 1 ACC-001 (PF ) Alzheimer s Disease MnB rlp2086 (PF ) 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) (PF ) Adolescent Meningitis, *Infant Meningitis Staph Aureus PF Smoking Cessation 1 New or Biosimilar * Note: Additional indications in 1 10
11 Pfizer Pipeline August 9, 2012 (cont d) Therapeutic Area Compound Name Mechanism of Action Taliglucerase alfa Enzyme Replacement Therapy Gaucher Disease (Biologic) (EU) bazedoxifeneconjugated estrogens Tissue Selective Estrogen Complex Menopausal Vasomotor Symptoms (EU) Xiapex (EU) Clostridial Collagenase for Injection Peyronie s Disease (Biologic) (EU) 3 Eraxis/Vfend Beta-D Glucan Synthase Inhibitor, Cyp P450 Mediated Alpha-lanosterol Demethylation Aspergillosis 3 Zithromax/chloroquine 5-OS Ribosome Inhibitor Malaria 3 bazedoxifeneconjugated estrogens Tissue Selective Estrogen Complex Menopausal Vasomotor Symptoms (U.S.) 3 Other Areas bosutinib Autosomal Dominant Polycystic Kidney of Disease Focus PF (filibuvir) Hepatitis C Virus tofacitinib (CP ) Transplant Rejection PH Chronic Obstructive Pulmonary Disease PF (GMI-1070) Vaso-occlusive crisis associated with Sickle Cell Disease PNU Tuberculosis RN6G (PF ) Age-Related Macular Degeneration (Biologic) 1 PF Chronic Obstructive Pulmonary Disease 1 PF Hemophilia (Biologic) 1 PF Muscular Dystrophies (Biologic) 1 New or 11
12 Projects Discontinued from Development since May 10, 2012 Compound Name Mechanism of Action Torisel FKBP-Rapamycin Associated Protein Renal Cell Carcinoma 2nd Line (after disease progression on or after Sutent therapy) 3 bapineuzumab Beta Amyloid Inhibitor Alzheimer s Disease (Biologic) 3 inotuzumab ozogamicin Indolent Non-Hodgkin s Lymphoma (Biologic) PF Diabetes Mellitus-Type 2 PF Acute Pain (currently in 1 for Chronic Pain) PF Diabetes Mellitus-Type 2 1 PF Severe Chronic Pain 1 PF Migraine (Biologic) 1 New or 12
Pfizer Pipeline. May 10, 2012
Pfizer Pipeline May 10, 2012 Disclaimer As some programs are still confidential, some candidates may not be identified in this list. In these materials, Pfizer discloses Mechanism of Action (MOA) information
Pfizer Pipeline. November 8, 2012
Pfizer Pipeline November 8, 2012 Disclaimer As some programs are still confidential, some candidates may not be identified in this list. In these materials, Pfizer discloses Mechanism of Action (MOA) information
Pfizer Pipeline. February 28, 2012
Pfizer Pipeline February 28, 2012 Disclaimer As some programs are still confidential, some candidates may not be identified in this list. In these materials, Pfizer discloses Mechanism of Action (MOA)
Pfizer Pipeline. As of May 12, 2011
Pfizer Pipeline As of May 12, 2011 Disclaimer As some programs are still confidential, some candidates may not be identified in this list. In these materials, Pfizer discloses Mechanism of Action (MOA)
Delivering Scientific Advances That Impact Patients Lives
Delivering Scientific Advances That Impact Patients Lives Geno Germano President / General Manager Specialty Care & Oncology Business Units J.P. Morgan Healthcare Conference January 11, 2011 Forward-Looking
Pfizer Worldwide Research & Development Presentation by Mikael Dolsten, M.D., PhD. Morgan Stanley Global Healthcare Conference September 13, 2010
Pfizer Worldwide Research & Development Presentation by Mikael Dolsten, M.D., PhD. Morgan Stanley Global Healthcare Conference September 13, 2010 Forward-Looking Statements Our discussions during this
Pfizer Pipeline. As of January 30, 2018
Pfizer Pipeline As of January 30, 2018 Disclaimer As some programs are still confidential, some candidates may not be identified in this list. In these materials, Pfizer discloses Mechanism of Action (MOA)
Pfizer Pipeline. As of May 1, 2018
Pfizer Pipeline As of May 1, 2018 Disclaimer As some programs are still confidential, some candidates may not be identified in this list. In these materials, Pfizer discloses Mechanism of Action (MOA)
Pfizer Independent Grants for Learning & Change Track 2- Annual Meetings: Submission Deadlines, Areas of Interest & Educational Goals
In order to submit a request for general meeting support through Track 2- Annual Meetings the answer to the following questions must be Yes : Does the activity align with Pfizer s areas of interest? (listed
HEALTH MATTERS, INC. SUMMARY OF PROJECTS AND KEY ACCOMPLISHMENTS TO 2016
Selected 2016 Highlights Epidemiologic research on chronic kidney disease and fistula patency, solid and hematologic malignancies Health economics and outcomes research on beta3-agonist treatment for overactive
Pfizer Independent Grants for Learning & Change Track 2- Annual Meetings: Submission Deadlines, Areas of Interest & Educational Goals
In order to submit a request for general meeting support through Track 2- Annual Meetings the answer to the following questions must be Yes : Does the activity align with Pfizer s areas of interest? (listed
CHRONIC TREATMENT GUIDELINES
CHRONIC TREATMENT GUIDELINES REGISTRATION OF CHRONIC CONDITIONS You can only access benefits for chronic medication, as listed below, if your prescribing/treating doctor or pharmacist registers your chronic
Summary of Strategic Competitive Analysis and Publication Planning
Summary of Strategic Competitive Analysis and Publication Planning Carole Alison Chrvala, PhD 919.545.2149 (Work) 919.951.5230 (Mobile) cchrvala@centurylink.net www.healthmattersmedwriting.com 1 Briefing
Cardiovascular Health Controlling Both HDL And LDL is Important
Cardiovascular Health Controlling Both HDL And LDL is Important Reducing the Risk of Coronary Heart Disease 3 Relative Risk In 4 Years 2 1 0 Increased Risk 25 55 85 HDL Cholesterol (mg/dl) 100 160 220
How much do you know about illnesses or health problems for your parents, grandparents, brothers, sisters, and/or children? 1 A lot Some None at all
Family Health History Please answer each question as honestly as possible. There are no right or wrong answers to nay of the questions. It is important that you answer as many questions as you can. We
Pfizer Global Medical Grants Annual Meetings: Submission Deadlines, Primary Areas of Interest, & Educational Goals
In order to submit a request for general meeting support for an Annual Meeting, the answers to the following questions must be Yes : Does the activity align with Pfizer s Primary Areas of Interest? (listed
Magellan Rx. A smarter approach to pharmacy benefits management
Magellan Rx A smarter approach to pharmacy benefits management Presented by: Cheri Caruso, VP of Sales, Magellan Rx Management Bryce Canfield, VP, Client Development, GoodRx A unique vision of care We
*Compounds with "In-house" in this column include ones discovered by collaborative research.
AGS67E Lymphoid malignancies P-I Injection In-house (ADC technology in-licensed from Seattle Genetics) AGS62P1 Acute myeloid leukemia P-I Injection In-house (ADC technology, EuCODE license from Ambrx)
Pharmacotherapy Handbook
Pharmacotherapy Handbook Eighth Edition Barbara G. Wells, PharmD, HP, FCCP, BCPP Dean and Professor Executive Director, Research Institute of Pharmaceutical Sciences School of Pharmacy, The University
Phoenix Remembrance Life
Phoenix Remembrance Life Field Underwriting Guide For agent use only. Not for distribution to the public as sales literature. Phoenix Remembrance Life is whole life insurance underwritten on a simplified
R&D Pipeline (May 2010)
R&D Pipeline (May 2010) 1 Global development (1) Filed Stage in the Most Advanced Territory YM617 tamsulosin Alpha-1 receptor antagonist Lower urinary tract syndrome in male patients (June 2007) New indication
R&D Pipeline (November 2005)
R&D Pipeline (November 2005) 1Japan (1)Filed Code No YM905 YM177 YM152 FK463 Generic Name (Filing Date ) solifenacin (Aug 2004) celecoxib (Dec 2002) finasteride (Dec1994) micafungin (July 2004) (Oct 2005)
R&D Pipeline (As of April 2017)
R&D Pipeline (As of April 2017) Underlined items indicate changes from the previous announcement on January 31, 2017. Oncology (1/2) MDV3100 enzalutamide Androgen receptor inhibitor Metastatic castration-resistant
R&D Pipeline (As of Apr 2018) Underlined items indicate changes from the previous announcement on Jan 31, 2018.
R&D Pipeline (As of Apr 2018) Underlined items indicate changes from the previous announcement on Jan 31, 2018. Oncology (1/2) MDV3100 enzalutamide Androgen receptor inhibitor Castration-resistant prostate
What prescribers need to know
HUMIRA Citrate-free presentations in an Electronic Medical Record (EMR) What prescribers need to know 2 / This is your guide to identifying HUMIRA Citrate-free presentations in your Electronic Medical
(212) Investors Contact: Ryan Crowe (212)
For immediate release: February 5, 2014 Media Contact: Sally Beatty (212) 733-6566 Investors Contact: Ryan Crowe (212) 733-8160 Pfizer And Merck To Collaborate On Innovative Anti-Cancer Combination Studies
R&D Pipeline (November 2006)
R&D Pipeline (November 2006) 1Japan (1)Filed Code No Generic Name (Filing Date ) Therapeutic Target Classification YM177 celecoxib (Dec 2002) Rheumatoid arthritis, osteoarthritis, low back pain, etc Cyclooxygenase-II
R&D Pipeline (May 2006)
R&D Pipeline (May 2006) 1Japan (1)Approved Product Name (Code No) Vesicare (YM905) Funguard (FK463) (Approval Date ) solifenacin (April 2006) micafungin (April 2006) Urinary frequency, urinary incontinence
Premium Specialty: Pediatrics
Premium Specialty: Pediatrics Credentialed Specialties include: Adolescent Medicine, Pediatric Adolescent, and Pediatrics This document is designed to be used in conjunction with the UnitedHealth Premium
2016 Health and Wellness Observances
2016 Health and Wellness Observances January 2016 Notes HealthCom Cervical Health Awareness Month National Birth Defects Prevention Month Cervical Cancer Screening Month National Blood Donor Month National
Past Medical History. Chief Complaint: Patient Name: Appointment Date: Page 1
Appointment Date: Page 1 Chief Complaint: (Please write reason, symptoms, condition or diagnosis that prompts your appointment) Past Medical History PERSONAL SKIN HISTORY YES NO Yes - Details Melanoma
List of Qualifying Conditions
List of Qualifying Conditions Cancer Conditions 1) Adrenal cancer 2) Bladder cancer 3) Bone cancer all forms 4) Brain cancer 5) Breast cancer 6) Cervical cancer 7) Colon cancer 8) Colorectal cancer 9)
Professional International Study Management
Professional International Study Management Services Phase I Study Consulting Phase II-IV IV Study Conduct for Drugs and Devices Protocol Design and Development Study Feasibilities Site Identification,
Remicade. Remicade (infliximab), Inflectra (infliximab-dyyb) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.02 Subsection: Gastrointestinal nts Original Policy Date: May 20, 2011 Subject: Remicade Page: 1 of
HELPING YOU AND YOUR PATIENTS TALK OPENLY ABOUT MODERATELY TO SEVERELY ACTIVE RA
SIMPONI ARIA (golimumab) is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) in combination with MTX, active psoriatic arthritis, and active ankylosing
Asthma J45.20 Mild, uncomplicated J45.21 Mild, with (acute) exacerbation J45.22 Mild, with status asthmaticus
A Fib & Flutter I48.0 Paroxysmal atrial fibrillation I48.1 Persistent atrial fibrillation I48.2 Chronic atrial fibrillation I48.3 Typical atrial flutter Asthma J45.20 Mild, uncomplicated J45.21 Mild, with
Enhanced cancer vaccine effectiveness with NKTR-214, a CD122 biased cytokine
SMi Immuno-Oncology, London Loui Madakamutil, Ph. D Vice President, Head for Discovery Enhanced cancer vaccine effectiveness with NKTR-214, a CD122 biased cytokine Sept 26-27 2018 Nektar Therapeutics San
Xeljanz (tofacitinib), Xeljanz XR (tofacitinib extended-release)
Market DC Xeljanz (tofacitinib), Xeljanz XR (tofacitinib extended-release) Override(s) Prior Authorization Quantity Limit Medications Xeljanz (tofacitinib) Approval Duration 1 year Quantity Limit May be
Remicade. Remicade (infliximab), Inflectra (infliximab-dyyb) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Remicade Page: 1 of 9 Last Review Date: June 22, 2017 Remicade Description Remicade (infliximab),
2015 PQRS Registry. Source Measure Title Measure Description CITIUS1
1 CQ-IQ covers 65 CMS defined measures that Eligible Providers (EPs) have to report on to assess quality of care provided to the patients. Version Supported: PQRS Registry 2015 65 measures Reporting Period:
Cimzia. Cimzia (certolizumab pegol) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.11 Subject: Cimzia Page: 1 of 5 Last Review Date: December 8, 2017 Cimzia Description Cimzia (certolizumab
Reproducibility with zebrafish models of human health and disease
Reproducibility with zebrafish models of human health and disease Monte Westerfield, University of Oregon, Eugene, USA Sponsored by the Office of the Director National Institutes of Health, the National
SCHEDULE OF CONTINUING EDUCATION COURSES FOR RN s and CNAs. January 2018 WALK INS ARE ACCEPTED BUT WE ADVISE STUDENTS TO PRE-REGISTER BEFORE THURSDAY
SCHEDULE OF CONTINUING EDUCATION COURSES FOR RN s and CNAs January 201 DATE DAY TIME TOPICS January 04 January 11 January 1 January 25 9:00AM 9:00AM 9:00AM 9:00AM 1. Understanding Fibromyalagia 2. Diabetes
SCHEDULE OF CONTINUING EDUCATION COURSES FOR RN s and CNAs. January 2018
January 201 DATE DAY TIME TOPICS TOTAL January 04 1. Understanding Fibromyalagia 2. Diabetes and Cardiovascular Disease 3. Prostate Cancer 4. Hepatitis C 5. Understanding Hepatitis B January 11 1. Dysphagia
SCHEDULE OF CONTINUING EDUCATION COURSES FOR RN s and CNAs. January 2019
January 2019 DATE DAY TIME TOPICS TOTAL January 03 1. Alcoholism 2. Nutrition for the Elderly 3. Uterine Fibroids 4. HIPAA 5.Arthritis 6. Childhood Obesity January 10 1. Understanding Epilepsy: Latest
Actemra (tocilizumab) CG-DRUG-81
Market DC Actemra (tocilizumab) CG-DRUG-81 Override(s) Prior Authorization Approval Duration 1 year Medications Line of Business Quantity Limit Actemra (tocilizumab) vials VA MCD and All L-AGP May be subject
INFLIXIMAB Remicade (infliximab), Inflectra (infliximab-dyyb), Renflexis (infliximab-abda)
RATIONALE FOR INCLUSION IN PA PROGRAM Background Remicade, Renflexis and Inflectra are tumor necrosis factor (TNFα) blockers. Tumor necrosis factor is an endogenous protein that regulates a number of physiologic
proposed set to a required subset of 3 to 5 measures based on the availability of electronic
CMS-0033-P 143 proposed set to a required subset of 3 to 5 measures based on the availability of electronic measure specifications and comments received. We propose to require for 2011 and 2012 that EP's
Genentech Research & Early Development
Genentech Research & Early Development Founders Research Centers 1 & 2 Founders Research Centers 1 & 2 Andrew Chan, M.D., Ph.D. Senior Vice President, Research Biology September 2017 gred focus areas Discovering
Development status of ONO-4538(nivolumab)1
Development status of ONO-4538(nivolumab)1 Development Code Target Disease JAPAN US/EU KOR/TAI ONO-4538 Melanoma(2 nd ~) Launched Launched (US) Filing (EU) Approved(KOR) Filing(TAI) ONO-4538 Melanoma(1
2018 MIPS Reporting Family Medicine
2018 MIPS Reporting Family Medicine Quality Reporting Requirements: Report on 6 quality measures or a specialty measure set Include at least ONE outcome or high-priority measure Report on patients of All-Payers
Barbara G. Wells, PharmD, FASHP, FCCP, BCPP Dean and Professor School of Pharmacy, The University of Mississippi Oxford, Mississippi
Barbara G. Wells, PharmD, FASHP, FCCP, BCPP Dean and Professor School of Pharmacy, The University of Mississippi Oxford, Mississippi Joseph T. DiPiro, PharmD, FCCP Panoz Professor of Pharmacy, College
Major R&D Pipeline As of January 2016
Major R&D Pipeline As of January 2016 Therapeutic area Cardiovascular- Metabolics Phase 1 Phase 2 Phase 3 Application DS-1040 (Acute ischemic stroke / TAFIa DS-2330 (Hyperphosphatemia) DS-9231/TS23 (Thrombosis
ESC 2018 Tafamidis Analyst Briefing. August 27, 2018
ESC 2018 Tafamidis Analyst Briefing August 27, 2018 1 Forward Looking Statements This presentation includes forward-looking statements about, among other things, a potential indication for Tafamidis for
Jefferies Healthcare Conference. June 6, 2018
Jefferies Healthcare Conference June 6, 2018 Forward-Looking Statements and Non-GAAP Financial Information Some statements in this presentation may be forward-looking statements for purposes of the Private
(U / Anti-HER3 antibody) n Pexidartinib (US) (PLX3397 / CSF-1R/KIT/FLT3-ITD. inhibitor)
Red: Major changes after the FY2015 Q3 financial announcement on January 29, 2016 Major R&D Pipeline Therapeutic area Oncology Cardiovascular- Metabolics Phase 1 Phase 2 Phase 3 Application n DS-3032 (US/JP)
CHRONIC MEDICINE PROGRAMME GENERAL INFORMATION LETTER
RAND WATER MEDICAL SCHEME RAND WATER MEDICAL SCHEME CHRONIC MEDICINE PROGRAMME GENERAL INFORMATION LETTER LIST OF CHRONIC CONDITIONS Conditions covered under s chronic medication benefit are detailed below.
January Intravenous Nurse Day ALL MONTH LONG SUN MON TUE WED THU FRI SAT. Blood Donor Month. Glaucoma Awareness Month
January 1 2 3 4 5 6 Blood Donor Month 7 8 9 10 11 12 13 Glaucoma Awareness Month Volunteer Blood Donor Month Cervical Health Awareness Month 14 15 16 17 18 19 20 Thyroid Awareness Month Birth Defects Prevention
Anesthesia Preoperative Patient History
Anesthesia Preoperative Patient History Please Complete and BRING WITH YOU to Your Anesthesia Appointment Patient Name: Date of Birth: Phone Number: Kind of Surgery You are Having: Date of Your Surgery:
Major Health Awareness Days in 2016
Major Health Awareness Days in 2016 Whole year International Year of Pulses January All summer Big Red BBQ (Kidney Foundation) National Cervical Health Awareness Month February Ovarian Cancer Awareness
AVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer
FOR IMMEDIATE RELEASE AVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer Study designed to build upon safety profile demonstrated
Rayos Prior Authorization Program Summary
Rayos Prior Authorization Program Summary FDA APPROVED INDICATIONS AND DOSAGE FDA-Approved Indications: 1 Agent Indication Dosage Rayos (prednisone delayedrelease tablet) as an anti-inflammatory or immunosuppressive
Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment
Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment 1 Introductions Peter Langecker, MD, PhD Executive Medical Director, Global Oncology Clinipace Worldwide Mark Shapiro Vice President
Simponi / Simponi ARIA (golimumab)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.51 Subject: Simponi / Simponi ARIA Page: 1 of 6 Last Review Date: September 15, 2016 Simponi / Simponi
Cimzia. Cimzia (certolizumab pegol) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Cimzia Page: 1 of 5 Last Review Date: March 17, 2017 Cimzia Description Cimzia (certolizumab pegol)
Etanercept for Treatment of Hidradenitis
Home Search Browse Resources Help What's New About Purpose Etanercept for Treatment of Hidradenitis This study is currently recruiting patients. Sponsors and Collaborators: University of Pennsylvania Amgen
Development status of ONO-4538(nivolumab)1
Development status of ONO-4538(nivolumab)1 Development Code Target Disease JAPAN US/EU KOR/TAI ONO-4538 Melanoma(2 nd ~) Launched Launched (US) Filing (EU) Approved(KOR) Filing(TAI) ONO-4538 Melanoma(1
Development pipeline (as of February 1, 2017)
Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for Consolidated Financial Results for FY2016 (IFRS) 13 Development pipeline (as of February 1, 2017) Oncology Additional indication name
SOURCES: U.S. Department of Labor, Bureau of Labor Statistics; the Federal Reserve Bank of Cleveland; the Commodity Research Bureau; and U.S.
SOURCES: U.S. Department of Labor, Bureau of Labor Statistics; the Federal Reserve Bank of Cleveland; the Commodity Research Bureau; and U.S. Department of Commerce, Bureau of Economic Analysis. Identified
R&D Pipeline (As of Jul 2018) Underlined items indicate changes from the previous announcement on Apr 26, 2018.
R&D Pipeline (As of Jul 2018) Underlined items indicate changes from the previous announcement on Apr 26, 2018. Oncology (1/2) MDV3100 enzalutamide (XTANDI ) Androgen receptor inhibitor Non-metastatic
Evolve180 / Ideal Northwest Health Profile
Evolve180 / Ideal Northwest Health Profile ABOUT YOU First Name: Last Name: Address: City: State: Zip: Phone: Email: Date of Birth: Age: Height: Occupation: How did you find out about our program? Marital
Pfizer Announces Modification To Ongoing Tofacitinib FDA Post- Marketing Requirement Study In Patients With Rheumatoid Arthritis
February 19, 2019 Media Contact: Neha Wadhwa M: +1 212-733-2835 E: Neha.Wadhwa@pfizer.com Investor Contact: Charles Triano O: +1 212-733-3901 E: Charles.E.Triano@pfizer.com Pfizer Announces Modification
Medical Reference Library Table of Contents
Medical Reference Library Table of Contents Alcoholism Anemia Anxiety Abdominal Aortic Aneurysm Asthma Atrial Fibrillation Attention Deficit Hyperactivity Disorder (ADHD) Barrett s Esophagus Bipolar Disorder
Are Specialty Pharmacy Drugs Worth the Cost? How Companies Can Make Them More Affordable.
Are Specialty Pharmacy Drugs Worth the Cost? How Companies Can Make Them More Affordable. BACKGROUND Your Host: Eric Bricker, MD Co-Founder & Chief Medical Officer - Compass Professional Health Services
Over. Signature of Patient/Parent/Guardian: Date: / / Date: / / Patient s Name: For ADULT Patients : Employer: Address: Occupation:
Date: / / Patient s Name: Address: Preferred Home: ( ) - Work: ( ) - Cell: ( ) - Text Message Reminders : Yes No Social Security #: Date of Birth: - - / / For ADULT Patients : Employer: Occupation: Spouse
Overview of Current Quality Measures that can be Impacted by Ambulatory Pharmacists
Overview of Current Quality Measures that can be Impacted by Ambulatory Pharmacists Measure Name Measure Domain Measure Focus Comment/Explanation CMS Value-based Purchasing Program (CMS VBP) AMI 30-day
HEALTH SERVICES POLICY & PROCEDURE MANUAL
PAGE 1 of 6 PURPOSE To establish basic understanding of indications and contraindications for transplantation of various organs. POLICY The N.C. Department of Correction, Division of Prisons, Health Services
Jefferies 2017 Global Healthcare Conference. Stephen Doberstein, Ph.D. Senior Vice President & Chief Scientific Officer
Jefferies 2017 Global Healthcare Conference Stephen Doberstein, Ph.D. Senior Vice President & Chief Scientific Officer June 7, 2017 This presentation includes forward-looking statements regarding Nektar
SAMPLE. Rencarex (Renal Cell Carcinoma)- Analysis and Forecasts to Reference Code: GDHC0004RCCDVR Publication Date: March 2012
Rencarex (Renal Cell Carcinoma)- Analysis and Forecasts to Reference Code: GDHC0004RCCDVR Publication Date: March 2012 The Renal Cell Carcinoma (RCC) Disease Therapeutics Market GlobalData s analysis suggests
A Review of FDA PRO Labeling ( ) Ari Gnanasakthy RTI Health Solutions
A Review of FDA PRO Labeling (2011-2015) Ari Gnanasakthy RTI Health Solutions SEVENTH ANNUAL PATIENT-REPORTED OUTCOME (PRO) CONSORTIUM WORKSHOP April 27-28, 2016 Silver Spring, MD Disclaimer The views
Intron A. Intron A (interferon alfa-2b) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Intron A Page: 1 of 6 Last Review Date: June 19, 2015 Intron A Description Intron A (interferon
Publication Plan 2017
Publication Plan 2017 A passion for turning high quality, independent research insights into actionable commercial intelligence. Why Spherix Global Insights? Our independent reports are designed, developed,
Egg Donor screening Questionnaire. How many years did you complete in high school?
Please tick ( ) and complete ALL questions. YOU YOUR PARTNER Full name Forename Surname Forename Surname Date of birth day / month / year day / month / year Address Height : Weight: Ethnicity Home Tel:
Quality Performance Measures. (Starter Set)
Quality Performance Measures (Starter Set) 1 Contents ADMINISTRATIVE MEASURES.4 HEART AND VASCULAR 5 Cardiology.5 Cardiovascular Surgery 5 Vascular..5 HOSPITAL CLINICAL SERVICES.6 Pathology 6 Radiation
Intron A. Intron A (interferon alfa-2b) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.07 Subject: Intron A Page: 1 of 6 Last Review Date: June 22, 2018 Intron A Description Intron A (interferon
Infliximab/Infliximab-dyyb DRUG.00002
Infliximab/Infliximab-dyyb DRUG.00002 Override(s) Prior Authorization Step Therapy Medications Remicade (infliximab) Inflectra (inflectra-dyyb) Approval Duration 1 year Comment Intravenous administration
CHRONIC MEDICATION PROGRAMME INCLUDES PRESCRIBED MINIMUM BENEFIT CHRONIC DISEASE LIST (CDL)
CHRONIC MEDICATION PROGRAMME INCLUDES PRESCRIBED MINIMUM BENEFIT CHRONIC DISEASE LIST (CDL) A. GENERAL INFORMATION LIST OF CHRONIC CONDITIONS Conditions covered under KeyHealth s chronic medication benefit
CLINICAL POLICY Department: Medical Management Document Name: Inlyta Reference Number: NH.PHAR.100 Effective Date: 05/12
Page: 1 of 5 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted
R&D Pipeline (As of Oct 2018) Underlined items indicate changes from the previous announcement on July 27, 2018.
R&D Pipeline (As of Oct 2018) Underlined items indicate changes from the previous announcement on July 27, 2018. Oncology (1/2) enzalutamide MDV3100 (XTANDI ) Androgen receptor inhibitor Non-metastatic
EVIDENCE-BASED VITAMIN AND MINERAL USAGE SUMMARY TABLE (APRIL 2002)
Acne Acrodermatitis Enteropathica Adrenal Support Age Related Cognitive Decline Alcoholism/Alcohol Withdrawal Alzheimer's Disease Amenorrhoea Anaemia Angina Anorexia Nervosa Anxiety Asthma Atherosclerosis
ARISTOTLE Demonstrated that ELIQUIS is the First Oral Anticoagulant to Significantly Reduce All-Cause Death
ELIQUIS (apixaban) was Superior to Warfarin for the Reduction of Stroke or Systemic Embolism with Significantly Less Major Bleeding in Patients with Atrial Fibrillation in Phase 3 ARISTOTLE Trial ARISTOTLE
Citi Global Healthcare Conference
Citi Global Healthcare Conference Francis Cuss, MB BChir, FRCP Chief Scientific Officer February 24, 2014 1 Forward-Looking Information During this meeting, we will make statements about the Company s
In your own words, please write the reason you are here. Please be specific, putting in dates as necessary. Use the back of the form if needed.
Name: SS# In your own words, please write the reason you are here. Please be specific, putting in dates as necessary. Use the back of the form if needed. Patient Medical, Surgical and Family History Review
Cimzia. Cimzia (certolizumab pegol) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.11 Section: Prescription Drugs Effective Date: April 1, 2018 Subject: Cimzia Page: 1 of 5 Last Review
WITBANK COALFIELDS MEDICAL AID SCHEME (WCMAS) CHRONIC MEDICINE PROGRAMME GENERAL INFORMATION LETTER
WITBANK COALFIELDS MEDICAL AID SCHEME (WCMAS) CHRONIC MEDICINE PROGRAMME GENERAL INFORMATION LETTER The Prescribed Minimum Benefit Chronic Disease List In terms of the Medical Scheme Act Regulations that
Corporate Overview June 2014 Jefferies Healthcare Conference NASDAQ: GLYC
Corporate Overview June 2014 Jefferies Healthcare Conference NASDAQ: GLYC Forward-Looking Statements To the extent that statements contained in this presentation are not descriptions of historical facts
(+1) Matti Ojanen (+44) Investor Contact: Jennifer M. Davis (+1)
For immediate release: October 24, 2012 Media Contact: Victoria Davis (+1) 347-558-3455 Matti Ojanen (+44) 7557-202-394 Investor Contact: Jennifer M. Davis (+1) 212-733-0717 Pfizer s XALKORI Receives Conditional
Term & Universal Life Guidelines - Simplified
- G.U.L. AIDS Alcoholism Within past 4 years: Within past 4 years: Within past 5 years: After 5 years, without relapse, no current use: : After 5 years since treatment: Less than 5 years: POSSIBLE STANDARD